TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need.

TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders.  

Shareholder Letter N°1 (in French) - 15/11/2016   

TxCell presentation - ARM EU Advanced Therapies Investor Day - 03/11/2016

 LAA Nov2016 FR           

Half-year financial results - Conference call and webcast

A conference call and webcast in English will be held on Wednesday, September 28 at 3:30pm CET. To participate: 

You may also download the presentation in PDF.

Following the live call, a replay will be available for 90 days. To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 303497#


2015 Registration Document (Document de Référence) - 24/05/2016   

Corporate Presentation - December 1st, 2016

 DDR 2014             Corporate Presentation

Arnaud Foussat, "Multiple ways to genetically alter T cells", MedNous, Vol 10, N° 7, July-August 2016, 6-7.

MedNous July-August 2016 issue - Arnaud Foussat commentary        




November 16-17, 2016
Jefferies London Healthcare Conference, London, UK


November 18-19, 2016
Actionaria, Paris, France


November 21-23, 2016
German Equity Forum, Frankfurt, Germany


November 29-30, 2016
Cell Therapy Manufacturing & Gene Therapy Congress, Amsterdam, Netherlands


November 30 - December 1, 2016
BioFIT, Lille, France